Antitumor Combinations Containing Anti Ceacam5 Antibody Drug Conjugates, Anti Vegfr 2 Antibodies And Anti Pd1/Pd L1 Antibodies

Sanofi
Application Awaiting Examination App No 202517095213 Chemical

Patent information

IP India · live record
Application number
202517095213
Filing date
03 October 2025
Status
Application Awaiting Examination
Publication number
52/2025
Publication type
INA
Invention field
Chemical

Abstract

The disclosure relates to a combination of (i) an antibody-drug conjugate (ADC) comprising an anti-CEACAM5 antibody, (ii) a VEGFR-2 inhibitor, and (iii) an anti-PD-1 antibody or anti-PD-L1 antibody, for use in the treatment of a cancer.

Applicants

2
France
SANOFI 46 avenue de la Grande Armée 75017 PARIS
U.S.A.
ELI LILLY AND COMPANY Lilly Corporate Center INDIANAPOLIS, Indiana 46285

Inventors

2
France
CHADJAA, Mustaphac/o SANOFI, Patent Department 46 avenue de la Grande Armée 75017 PARIS
U.S.A.
DENNIS, Philipc/o SANOFI, Patent Department 450 Water Street CAMBRIDGE, Massachusetts 02141

Documents

Sign in to open
Application documents
1 202517095213-TRANSLATIOIN OF PRIOIRTY DOCUMENTS ETC. [03-10-2025(online)].pdf 03 Oct 2025
2 202517095213-STATEMENT OF UNDERTAKING (FORM 3) [03-10-2025(online)].pdf 03 Oct 2025
4 202517095213-Sequence Listing in PDF [03-10-2025(online)].pdf 03 Oct 2025
5 202517095213-REQUEST FOR EXAMINATION (FORM-18) [03-10-2025(online)].pdf 03 Oct 2025
6 202517095213-FORM 18 [03-10-2025(online)].pdf 03 Oct 2025
7 202517095213-FORM 1 [03-10-2025(online)].pdf 03 Oct 2025
8 202517095213-DRAWINGS [03-10-2025(online)].pdf 03 Oct 2025
9 202517095213-DECLARATION OF INVENTORSHIP (FORM 5) [03-10-2025(online)].pdf 03 Oct 2025
10 202517095213-COMPLETE SPECIFICATION [03-10-2025(online)].pdf 03 Oct 2025
11 202517095213-FORM-26 [09-12-2025(online)].pdf 09 Dec 2025